24/7 Market News Snapshot 28 October, 2024 – Anixa Biosciences, Inc. (NASDAQ:ANIX)

October 28, 2024

DENVER, Colo., 28 October, 2024 (247marketnews.com) – (NASDAQ:ANIX) are discussed in this article.
Anixa Biosciences, Inc. (ANIX) is experiencing significant market momentum, with shares opening at $3.43 and currently trading at $3.97, reflecting a remarkable increase of 22.15%. This development signifies heightened investor interest, as evidenced by a trading volume of 536.13K shares. The previous closing price stood at $3.25, indicating an upward trajectory that has investors closely monitoring potential further advancements in the company’s innovative bioscience initiatives.

In tandem with its impressive market performance, Anixa has also achieved a significant milestone in its clinical development efforts. The company is set to present additional data from its Phase 1 clinical trial of a novel breast cancer vaccine at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting scheduled for November 6-10, 2024. This pioneering trial is a collaborative endeavor with the Cleveland Clinic, bolstered by financial support from the U.S. Department of Defense.

The upcoming presentation, led by Dr. Emily Rhoades, FDA/IND Trial Program Manager at Cleveland Clinic, is titled “Phase I Trial of alpha-lactalbumin vaccine in high-risk operable triple-negative breast cancer (TNBC) and patients at high genetic risk for TNBC.” Set for November 8, 2024, the presentation aims to offer insights into innovative immunotherapy approaches to combat breast cancer.

Anixa’s vaccine operates on a unique mechanism, targeting α-lactalbumin, a protein often absent from aging tissues yet present in certain breast cancers. By activating the immune system against this “retired” protein, the vaccine provides a proactive strategy to prevent tumor development. Promising early trial results have demonstrated a solid safety profile and robust immune responses in a majority of participants.

As Anixa prepares to unveil its findings at SITC, the scientific community looks forward to insights that have the potential to redefine breast cancer immunotherapy, reinforcing Anixa’s commitment to pioneering novel therapies in cancer prevention and treatment. The findings will be available on Anixa’s website after the event, marking a significant chapter in the ongoing battle against cancer.

Related news for (ANIX)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.